These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36100328)

  • 1. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.
    Bhardwaj S; Kesari KK; Rachamalla M; Mani S; Ashraf GM; Jha SK; Kumar P; Ambasta RK; Dureja H; Devkota HP; Gupta G; Chellappan DK; Singh SK; Dua K; Ruokolainen J; Kamal MA; Ojha S; Jha NK
    J Adv Res; 2022 Sep; 40():207-221. PubMed ID: 36100328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review.
    Barman NC; Khan NM; Islam M; Nain Z; Roy RK; Haque A; Barman SK
    Neurol Ther; 2020 Dec; 9(2):419-434. PubMed ID: 33089409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease.
    Giau VV; Lee H; Shim KH; Bagyinszky E; An SSA
    Clin Interv Aging; 2018; 13():221-233. PubMed ID: 29445268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not Aβ.
    Kwart D; Gregg A; Scheckel C; Murphy EA; Paquet D; Duffield M; Fak J; Olsen O; Darnell RB; Tessier-Lavigne M
    Neuron; 2019 Oct; 104(2):256-270.e5. PubMed ID: 31416668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
    Kuruvilla J; Sasmita AO; Ling APK
    Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.
    Park H; Oh J; Shim G; Cho B; Chang Y; Kim S; Baek S; Kim H; Shin J; Choi H; Yoo J; Kim J; Jun W; Lee M; Lengner CJ; Oh YK; Kim J
    Nat Neurosci; 2019 Apr; 22(4):524-528. PubMed ID: 30858603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.
    Crews L; Rockenstein E; Masliah E
    Brain Struct Funct; 2010 Mar; 214(2-3):111-26. PubMed ID: 20091183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage.
    Sun J; Carlson-Stevermer J; Das U; Shen M; Delenclos M; Snead AM; Koo SY; Wang L; Qiao D; Loi J; Petersen AJ; Stockton M; Bhattacharyya A; Jones MV; Zhao X; McLean PJ; Sproul AA; Saha K; Roy S
    Nat Commun; 2019 Jan; 10(1):53. PubMed ID: 30604771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders.
    De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient SSA-mediated precise genome editing using CRISPR/Cas9.
    Li X; Bai Y; Cheng X; Kalds PGT; Sun B; Wu Y; Lv H; Xu K; Zhang Z
    FEBS J; 2018 Sep; 285(18):3362-3375. PubMed ID: 30085411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 for treating hereditary diseases.
    Mani I
    Prog Mol Biol Transl Sci; 2021; 181():165-183. PubMed ID: 34127193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice.
    Duan Y; Ye T; Qu Z; Chen Y; Miranda A; Zhou X; Lok KC; Chen Y; Fu AKY; Gradinaru V; Ip NY
    Nat Biomed Eng; 2022 Feb; 6(2):168-180. PubMed ID: 34312508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer's Disease.
    Narayanan SE; Sekhar N; Rajamma RG; Marathakam A; Al Mamun A; Uddin MS; Mathew B
    Curr Protein Pept Sci; 2020; 21(12):1164-1173. PubMed ID: 32957903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease.
    Rohn TT; Kim N; Isho NF; Mack JM
    J Alzheimers Dis Parkinsonism; 2018; 8(3):. PubMed ID: 30090689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of CRISPR/Cas9 in Alzheimer's Disease.
    Lu L; Yu X; Cai Y; Sun M; Yang H
    Front Neurosci; 2021; 15():803894. PubMed ID: 34992519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology.
    Nagata K; Takahashi M; Matsuba Y; Okuyama-Uchimura F; Sato K; Hashimoto S; Saito T; Saido TC
    Nat Commun; 2018 May; 9(1):1800. PubMed ID: 29728560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2
    Ortiz-Virumbrales M; Moreno CL; Kruglikov I; Marazuela P; Sproul A; Jacob S; Zimmer M; Paull D; Zhang B; Schadt EE; Ehrlich ME; Tanzi RE; Arancio O; Noggle S; Gandy S
    Acta Neuropathol Commun; 2017 Oct; 5(1):77. PubMed ID: 29078805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of melatonin receptor 1 by CRISPR-Cas9 activator ameliorates cognitive deficits in an Alzheimer's disease mouse model.
    Park H; Kim J
    J Pineal Res; 2022 Apr; 72(3):e12787. PubMed ID: 35133672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.